Pharmaceuticals
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
Pacylex Pharmaceuticals Showcases Promising NMT Inhibitors at BIO Annual Meeting
Pacylex Pharmaceuticals Inc. highlights its innovative N-myristoyltransferase inhibitors (NMTis) at the BIO International Convention, showcasing potential breakthroughs in cancer treatment through oral zelenirstat and ADC payloads.
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention
Tonix Pharmaceuticals Holding Corp. is set to present at the 2025 BIO International Convention, highlighting its advancements in pain management and public health solutions, including a potential new treatment for fibromyalgia.
Medicus Pharma Ltd. (NASDAQ: MDCX) Strategically Positions Itself in the Rapidly Growing $5 Trillion Biotech Market
Medicus Pharma Ltd. is leveraging the aging global population and technological advancements in biopharma to address chronic diseases, positioning itself for significant growth in the $5 trillion biotech market by 2034.
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.
Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
Tevard Biosciences has appointed Dr. Elisabeth Gardiner as its new Chief Scientific Officer, marking a significant step in advancing its tRNA-based therapies for genetic diseases, with implications for treating conditions like Duchenne Muscular Dystrophy and TTN-related dilated cardiomyopathy.
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology
Nutriband Inc. has been granted a U.S. patent for its Aversa(TM) technology, marking a significant step forward in the fight against drug abuse and misuse with its abuse-deterrent transdermal products.
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients with FDA Orphan Drug Designation
Soligenix Inc. advances in the treatment of Cutaneous T-cell lymphoma (CTCL) with HyBryte(TM), a photodynamic therapy showing promise in clinical trials and receiving Orphan Drug Designation, addressing a critical need for effective therapies in this rare disease.
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform, Bolstering Oncology Portfolio
OncoX BioPharma Inc., an affiliate of ABVC BioPharma, has acquired the Lycopenoid Lycogen® platform, a move that could generate significant revenue through a scalable royalty strategy and strengthen ABVC's position in botanical oncology innovation.
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in CMV Management for Transplant Patients
Kamada Ltd. is amplifying its commitment to organ transplant patients by enhancing awareness and research around CYTOGAM, its treatment for cytomegalovirus (CMV), a potentially deadly complication for transplant recipients.
Nutriband Inc. Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
Nutriband Inc. is pioneering a novel transdermal delivery system for buprenorphine, aiming to address the opioid epidemic with safer treatment options, potentially revolutionizing pain and addiction therapies.
Scinai Immunotherapeutics Clears Italian Regulatory Hurdle for Pincell Acquisition
Scinai Immunotherapeutics Ltd. has received Italian regulatory approval to proceed with its option to acquire Pincell S.r.l., a move that could significantly expand its inflammation and immunology pipeline with Pincell's promising monoclonal antibody, PC111.
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit
CNS Pharmaceuticals Inc. will present promising data on its brain-penetrating taxane candidate, TPI 287, at the upcoming Brain Tumor Biotech Summit, highlighting potential breakthroughs in treating glioblastoma and other CNS tumors.
Telomir Pharmaceuticals Reports Preclinical Breakthrough in Age-Reversal with Telomir-1
Telomir Pharmaceuticals' preclinical results for Telomir-1 show promising age-reversal effects in a zebrafish model of Werner Syndrome, highlighting potential advancements in longevity science.
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025
Tonix Pharmaceuticals Holding Corp. is set to present its latest research at the Annual European Congress of Rheumatology (EULAR) 2025, highlighting advancements in rheumatologic conditions and its broader pipeline.
Nutriband Inc. to Showcase Innovations at Noble Capital Markets Emerging Growth Virtual Conference
Nutriband Inc. (NASDAQ: NTRB) is set to present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, highlighting its advancements in abuse-deterrent transdermal pharmaceutical products, a critical step in addressing the opioid crisis.
Repertoire Immune Medicines Strengthens Leadership with Appointment of Dr. Robert Andtbacka as Chief Medical Officer
Repertoire Immune Medicines appoints Dr. Robert Andtbacka as Chief Medical Officer, marking a significant step in advancing its pipeline of T cell-targeted therapies for cancer and autoimmune diseases.
Nutriband Inc.'s AVERSA Technology Poised for FDA Approval with Significant Market Potential
Nutriband Inc.'s innovative AVERSA abuse-deterrent patch technology, targeting the misuse of transdermal patches like fentanyl, is on its way to FDA approval, with an estimated annual market potential of $800 million.
Pfizer Faces Lawsuit Over Contraceptive Injection Linked to Brain Tumors
Hundreds of women from the U.S. and U.K. are suing Pfizer after a study linked its contraceptive injection to a significantly increased risk of brain tumors, highlighting potential health risks associated with pharmaceutical products.
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
CareMetx Strengthens Leadership Team with Appointment of Brian Flaherty as Chief Commercial Officer
CareMetx enhances its leadership by appointing Brian Flaherty as Chief Commercial Officer, aiming to improve patient access to specialty therapies through strategic commercial initiatives.
Jean Witz Joins Wilson Sonsini as Senior Patent Counsel, Bolstering Firm's Expertise in Biotechnology and Pharmaceuticals
Jean Witz, with nearly 40 years of experience in patent law and a distinguished career at the USPTO, joins Wilson Sonsini as senior patent counsel, enhancing the firm's capabilities in biotechnology, pharmaceuticals, and chemical engineering.
Catalio Capital Invests in $130 Million Series B Funding for GlycoEra to Advance Autoimmune Disease Treatments
Catalio Capital Management has participated in a $130 million Series B funding round for GlycoEra AG, a Swiss biotech firm, to develop innovative treatments for autoimmune diseases, marking a significant step forward in life sciences investment and healthcare innovation.
Telomir Pharmaceuticals Advances Telomere-Targeting Drug, Seeks Strategic Partnerships
Telomir Pharmaceuticals is preparing to submit an Investigational New Drug (IND) application for Telomir-1, a potential breakthrough small molecule targeting aging mechanisms, with plans to explore strategic collaborations at the BIO International Convention 2025.
Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.
NanoViricides Reveals Breakthrough Antiviral Platform at BIO International Convention
NanoViricides will showcase its novel NV-387 broad-spectrum antiviral drug candidate, which demonstrates promising preclinical efficacy against multiple viral infections, potentially revolutionizing viral treatment approaches.
Quantum BioPharma Advances Clinical Trial for MCAS Pain Treatment
Quantum BioPharma has received Australian ethics approval for a Phase 2 clinical trial of FSD202, a potential treatment for chronic pain associated with Mast Cell Activation Syndrome (MCAS), signaling progress in addressing a challenging medical condition.
Nutriband Seeks to Revolutionize Transdermal Pain Management Through Innovative Abuse-Deterrent Technology
Nutriband is developing a groundbreaking transdermal drug delivery platform aimed at addressing pain management challenges in the wake of the opioid crisis, focusing on creating safer, more accessible opioid therapies.
Soligenix Develops Novel Therapy to Address Antibiotic-Resistant Bacterial Infections
Soligenix's SGX943 represents a potential breakthrough in combating antibiotic-resistant bacteria, offering a novel broad-spectrum therapy that could help address a critical public health challenge.
Nutriband Advances Opioid Patch Technology with Potential Abuse-Deterrent Solution
Nutriband is making significant progress toward commercializing its AVERSA Fentanyl technology, partnering with Kindeva Drug Delivery to develop a potentially groundbreaking opioid pain patch with abuse-deterrent properties.